

Curriculum Vitae

Name : Chul Won Jung, M.D., Ph.D.

Date of Birth : 1962. Sep 24th,

Place of Birth : Daejeon, Korea

Address : Department of Medicine, Samsung Medical Center, #50, Il Won-dong, Gang Nam-gu, Seoul,
135-710, Korea

Telephone : +82-2-3410-3452

Fax : +82-2-3410-1754

E-mail : leukemia1@skku.edu

Specialty

Hematology

Clinic

Professor, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea

Special Interests

Acute leukemia, Chronic leukemia, Myelodysplastic syndrome, Hematopoietic Stem Cell Transplantation

Education

Doctor of Medicine, Seoul National University College of Medicine, Seoul, Korea, 1987

Master of Science, Graduate School, Seoul National University College of Medicine, Seoul, Korea, 1997

Doctor of Philosophy, Graduate School, Chungbuk National University, Cheongju, Chungbuk, Korea,
2000

Postgraduate Training

Internship : 1987 Mar – 1988 Feb, Seoul National University Hospital, Seoul, Korea

Military Service : 1988 Feb – 1991 Apr, Army, Korea

Residency : 1991 May – 1995 Feb, Internal Medicine, Seoul National University Hospital, Seoul, Korea

Fellowship : 1995 Feb – 1996 Mar, Hematology/Oncology, Department of Internal Medicine, Seoul
National University Hospital, Seoul, Korea

Professional Experience

Clinical Instructor : 1996 Mar – 1997 Aug, Department of Internal Medicine, Choong-Ang University Hospital, Seoul, Korea

Assistant Professor : 1997 Sep – 2001 Feb, Department of Internal Medicine, Choong-Ang University School of Medicine, Seoul, Korea

Invited Specialist : 2001 Mar – 2002 Feb, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea

Associate Professor : 2002 Mar – 2008 Mar, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Professor : 2008 Apr- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Post-Doc Fellowship : 2004 Feb – 2005 Feb, Transplantation Biology, Clinical Division, Fred-Hutchinson Cancer Research Center, Seattle, WA

Medical Society Membership

American Society of Hematology

Korean Society of Hematology

Korean Society of Oncology

Korean Society of Hematopoietic Stem Cell Transplantation

Publications

1. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea. Shin J, Koh Y, Yoon SH, Cho JY, Kim DY, Lee KH, Kim HJ, Ahn JS, Kim YK, Park J, Sohn SK, Moon JH, Lee YJ, Yoon S, Lee JO, Cheong JW, Kim KH, Kim SH, Kim HG, Kim H, Nam SH, Do YR, Park SG, Park SK, Bae SH, Song HH, Shin DY, Oh D, Kim MK, Jung CW, Park S, Kim I. Shin J, et al. *Cancer Med.* 2018 May;7(5):1814-1823.
2. Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. Park S, Choi H, Kim HJ, Ahn JS, Kim HJ, Kim SH, Mun YC, Jung CW, Kim DDH. Park S, et al. *Ann Hematol.* 2018 Jun;97(6):955-965.

3. HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, Park EJ, Park JH, Kim HJ, Kim SH, Kim HJ, Ahn JS, Sohn SK, Moon JH, Jung CW, Park S, Lipton JH, Kimura S, Kim JW, Kim DDH. *Leukemia*. 2019 Jun;33(6):1439-1450.
4. Different prognostic effects of core-binding factor positive AML with Korean AML registry data. Shin HJ, Min WS, Min YH, Cheong JW, Lee JH, Kim IH, Hong DS, Ahn JS, Kim HJ, Lee WS, Jung CW, Jang JH, Park Y, Kim HJ; Korean Society of Hematology AML/MDS Working Party. Shin HJ, et al. *Ann Hematol*. 2019 May;98(5):1135-1147
5. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. Fujishima N, Uchida T, Onishi Y, Jung CW, Goh YT, Ando K, Wang MC, Ono C, Matsumizu M, Paccagnella ML, Sleight B, Vandendries E, Fujii Y, Hino M. Fujishima N, et al. *Int J Hematol*. 2019 Dec;110(6):709-722.
6. TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. Turkina A, Wang J, Mathews V, Saydam G, Jung CW, Al Hashmi HH, Yassin M, Le Clanche S, Miljkovic D, Slader C, Hughes TP. Turkina A, et al. *Br J Haematol*. 2020 Mar 30.
7. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Lee JH, Faderl S, Pagel JM, Jung CW, Yoon SS, Pardanani AD, Becker PS, Lee H, Choi J, Lee K, Kim M, Cortes JE. Lee JH, et al. *Blood Adv*. 2020 May 12;4(9):2032-2043
8. Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization. Lee KW, Park JB, Park H, Kwon Y, Lee JS, Kim KS, Chung YJ, Rhu JS, Choi S, Kwon GY, Kim HJ, Kang ES, Jung CW, Shin EC, Kawai T, Kim SJ, Joh JW. Lee KW, et al. *Transplantation*. 2020 Jul;104(7):1472-1482

Signature :

Date :